Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HYCAT cost-effectiveness study by Hillman compares total costs of drug treatment to placebo.

Executive Summary

HYCAT COST-EFFECTIVENESS ANALYSIS OF HYTRIN v. PLACEBO was conducted by Alan Hillman, MD, University of Pennsylvania, to compare direct medical costs of terazosin and placebo in the 2,084-patient Hytrin Community Assessment Trial. Hillman looked at costs from hospitalizations, emergency care, outpatient/ambulatory care and medication use. Costs were similar for placebo- and Hytrin-treated patients: the added drug costs for the active ingredient were balanced by reduced costs from hospitalization and emergency care. Costs of services were provided from the perspective of a managed care organization and derived from a database of large employers health care claims representing 7.2 mil. insured individuals nationwide.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026124

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel